NCT00215358
Completed
Phase 2
Study in Patients With Asthma
Dey1 site in 1 country32 target enrollmentJuly 2002
ConditionsAsthma
DrugsFormoterol Fumarate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Dey
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Measure of lung function.
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Require regular use of an inhaled Beta-2-selective adrenergic agent
Exclusion Criteria
- •Active acute or chronic disorders of the respiratory system within one month prior to screening
- •Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history
- •Recent surgical interventions such as lung lobectomy or resection (\< one year), or cardiothoracic interventions
- •Life-threatening systemic and debilitating diseases.
Outcomes
Primary Outcomes
Measure of lung function.
Secondary Outcomes
- Change in lung function, vital signs, physical examinations, clinical laboratory assessments, and adverse event reporting.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215371Dey32
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215397Dey16
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215410Dey36
Completed
Phase 3
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthmaNCT00393952SkyePharma AG557
Completed
Phase 3
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With AsthmaAsthmaNCT00393991SkyePharma AG475